Natera, Inc.NTRAEarnings & Financial Report
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendment...
NTRA Q4 FY2025 Key Financial Metrics
Revenue
$665.5M
Gross Profit
N/A
Operating Profit
$-22.8M
Net Profit
$47.3M
Gross Margin
N/A
Operating Margin
-3.4%
Net Margin
7.1%
YoY Growth
39.8%
EPS
$0.36
Natera, Inc. Q4 FY2025 Financial Summary
Natera, Inc. reported revenue of $665.5M (up 39.8% YoY) for Q4 FY2025, with a net profit of $47.3M (up 187.9% YoY) (7.1% margin).
Key Financial Metrics
| Total Revenue | $665.5M |
|---|---|
| Net Profit | $47.3M |
| Gross Margin | N/A |
| Operating Margin | -3.4% |
| Report Period | Q4 FY2025 |
Natera, Inc. Annual Revenue by Year
Natera, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.3B).
Natera, Inc. Quarterly Revenue & Net Profit History
Natera, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $665.5M | +39.8% | $47.3M | 7.1% |
| Q3 FY2025 | $592.2M | +34.7% | $-87.5M | -14.8% |
| Q2 FY2025 | $546.6M | +32.2% | $-100.9M | -18.5% |
| Q1 FY2025 | $501.8M | +36.5% | $-66.9M | -13.3% |
| Q4 FY2024 | $476.1M | +53.0% | $-53.8M | -11.3% |
| Q3 FY2024 | $439.8M | +63.9% | $-31.6M | -7.2% |
| Q2 FY2024 | $413.4M | +58.1% | $-37.5M | -9.1% |
| Q1 FY2024 | $367.7M | +52.1% | $-67.6M | -18.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $367.7M | $413.4M | $439.8M | $476.1M | $501.8M | $546.6M | $592.2M | $665.5M |
| YoY Growth | 52.1% | 58.1% | 63.9% | 53.0% | 36.5% | 32.2% | 34.7% | 39.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.47B | $1.52B | $1.59B | $1.66B | $1.73B | $1.76B | $1.82B | $2.40B |
| Liabilities | $674.1M | $680.5M | $712.4M | $465.3M | $492.7M | $510.9M | $569.3M | $685.9M |
| Equity | $794.1M | $836.5M | $878.5M | $1.20B | $1.24B | $1.25B | $1.25B | $1.71B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $27.0M | $4.0M | $51.8M | $52.9M | $44.5M | $37.6M | $59.4M | $73.9M |